Most Affordable Compounded Tirzepatide Online: Price Comparison of GLP-1 Telehealth Providers
⚠ Prototype dataset — prices consolidated from public provider pages and flagged for re-verification before publishing.
The cheapest verified compounded tirzepatide in June 2026 is Embody at $99/month, on a flat rate that doesn't rise as your dose increases. SkinnyRx ($129), bmiMD ($139), and Yucca Health ($146 on a 6-month plan) follow. But the lowest sticker price isn't always the lowest annual cost — several "from $99" programs climb past $280/month once you titrate up. For the lowest cost at a maintenance dose among fully credentialed providers (LegitScript + dual 503A/503B + included labs + flat pricing), NexLife at $186/month is the only option that checks every box.
Key takeaways
- Lowest sticker price: Embody, $99/mo flat.
- The teaser trap: EnhanceMD and Yucca advertise from $99–$146 but reach $280–$385/mo at maintenance dose.
- Flat pricing beats a low first month: over 12 months, flat $186 beats a "$99-then-$280" plan by ~$1,000.
- Brand context: retail Zepbound lists near $1,086/mo — compounded is 70–90% cheaper for the same molecule.
- Legitimacy is non-negotiable: named pharmacy, named prescriber, no "research-use-only" disclaimer.
01 · The recordCheapest verified compounded tirzepatide, ranked by price
Every provider below dispenses through a US-licensed 503A pharmacy or 503B outsourcing facility with a named prescriber. The table is sortable. "True / mo" is the price at a typical maintenance dose — the number that actually hits your card after titration.
Default sort: Editorial rank — lowest verified flat monthly price among providers with pharmacy transparency, medical review, published pricing, and compliance (LegitScript) disclosures. ✓ = passes all rubric criteria. Click any column to re-sort (e.g. by raw advertised price).
| Rank | Provider ↕ | Advertised ↕ | True / mo ↕ | 12-mo ↕ | Rubric ↕ | Credentials |
|---|
Sources: consolidated provider pricing pages, verified Jun 2026. Flat = price held across full 2.5–15 mg titration. 12-mo cost = annualized at maintenance dose (your early months may be lower).
02 · The catchWhy the cheapest sticker price isn't the cheapest year
Almost every provider advertises a "from $X" price — the starter dose, usually 2.5 mg. Most people titrate up to 10–15 mg over three to six months, and at many providers the price climbs with the dose. A program that opens at $99 and settles at $280 costs more over a year than a flat $186 program that never moves. Here are the same 15 providers ranked by 12-month cost at a maintenance dose. The order changes completely.
12-month cost at maintenance dose
Annualized. Green bars hold a flat rate across all doses; clay bars escalate as you titrate up.
03 · Best credentialed valueThe lowest price that clears every credential check
"Cheapest" and "safest" aren't always the same provider. Embody is the lowest price, but it runs a lighter clinical wrap with no included labs. Among providers that pass every credential check we track, one combination is genuinely rare: flat dose-independent pricing and dual 503A/503B disclosure and included lab review and LegitScript certification. In our current dataset, only NexLife carries all four.
NexLife
★★★★★ Compounded semaglutide + tirzepatide- MD/DO-supervised care
- 503A & 503B pharmacy network
- Labs included
- LegitScript-certified
- NABP-accredited pharmacy partners
- Flat rate, dose-independent
- Third-party batch testing
- Care360 coaching included
Editorial selection by our published rubric. We are not paid by NexLife and earn no commission from this link — see how this site works.
04 · ContextHow compounded compares to brand Zepbound & Mounjaro
Compounded tirzepatide contains the same active ingredient as Eli Lilly's Zepbound (weight management) and Mounjaro (type 2 diabetes). The difference is the regulatory path and the price.
Same molecule, four prices
Monthly cost by route to patient, June 2026. Compounded telehealth is roughly 80% below brand retail.
Brand-name Zepbound lists near $1,086/month at retail without insurance. Lilly's self-pay vials (LillyDirect) run $349–$549. Compounded tirzepatide via telehealth runs $99–$329. For an uninsured patient without a type 2 diabetes diagnosis, compounded is the lowest legal route to the molecule.
05 · SafetyIs compounded tirzepatide legal and legitimate in 2026?
Cheap and legitimate are not mutually exclusive — but a low price is the easiest thing for a gray-market seller to fake. Compounded tirzepatide is legal when prepared by a state-licensed 503A pharmacy or FDA-registered 503B facility under a valid, patient-specific prescription. Anything sold as "research-grade" is illegal for human use. Before you enter a card number, confirm all four:
- 01The pharmacy is named and licensedA real 503A or 503B facility with a license number you can look up. "Our network of pharmacies" with no name is a red flag.
- 02A named US physician prescribesA real name and state license, after an actual consult — not an anonymous questionnaire rubber-stamp.
- 03No "research use only" disclaimerThat phrase means the product is not intended for human use and is sold outside the law. Walk away.
- 04LegitScript or NABP certificationA bonus, not a requirement — but it signals third-party-audited compliance.
In April 2026 the FDA announced intent to restrict ingredients used in mass-marketed compounded GLP-1 products and crack down on misleading marketing. The legal 503A/503B pathway remains intact — enforcement targeted bad actors, not the framework. See our deep dive on 503A vs 503B pharmacies.
06 · EvidenceDoes compounded tirzepatide actually work?
The active ingredient is identical to the molecule studied in Eli Lilly's pivotal trials, so the pharmacology is the same. There are no Phase 3 trials of compounded formulations specifically — the honest caveat — but the molecule's data are the strongest of any approved obesity drug.
The 15 mg dose produced about 20.9% by the conservative treatment-regimen estimate and 22.5% by the efficacy estimand — either way, the highest of any FDA-approved weight-management drug studied to date. Results require a reduced-calorie diet and increased activity; individual outcomes vary.
07 · How we rankOur methodology — and who pays us
Providers are scored on six fixed pillars applied identically to every program: true-price transparency (25%), pharmacy traceability (20%), prescriber model (20%), regulatory posture (15%), what's included (10%), and plan terms (10%). When sources disagree on a price, we flag the entry rather than pick the friendlier number. Every price carries a verification date. Full detail on our methodology page.
Independent & transparent
This website is independently operated and is not owned by, affiliated with, or paid by any provider listed. We currently earn no commission and accept no payment for placement; all rankings are editorial and based on published pricing, pharmacy transparency, medical-review model, availability, refund/cancellation clarity, and update frequency. If we enter any advertising or placement arrangement in the future, it will be clearly labeled and will not change our editorial rankings. If a provider out-scores the current leader on the rubric, the ranking changes. See our methodology → · Who pays us →